Compile Data Set for Download or QSAR
Report error Found 32 Enz. Inhib. hit(s) with all data for entry = 10296
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525567(US11174248, Example 40 | US11174248, Example 41 | ...)
Affinity DataIC50: 0.900nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525570((S)-5-(1-(6-(2-(2- hydroxypropan-2- yl)morpholino)...)
Affinity DataIC50: 0.900nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525553(US11174248, Example 15 | 5-(1-(6-(3- (hydroxymethy...)
Affinity DataIC50: 1.20nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525567(US11174248, Example 40 | US11174248, Example 41 | ...)
Affinity DataIC50: 1.20nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525566(5-(1-(6-(8-methyl-5-oxa- 2,8- diazaspiro[3.5]nonan...)
Affinity DataIC50: 1.30nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525549(5-(1-(6-(4- (hydroxymethyl)-2- azabicyclo[2.1.1]he...)
Affinity DataIC50: 1.5nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525572((S)-5-(1-(6- (hexahydropyrazino[2,1- c][1,4]oxazin...)
Affinity DataIC50: 2nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50535644(CHEMBL4562534 | US11174248, Example 24)
Affinity DataIC50: 2.60nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525563(5-(1-(6-(3-hydroxy-3- methylazetidin-1- yl)pyrimid...)
Affinity DataIC50: 2.90nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525550((R)-5-(1-(6-(3-(hydroxy- methyl)pyrrolidin- 1-yl)p...)
Affinity DataIC50: 2.90nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525552((S)-5-(1-(6-(2-(hydroxy- methyl)morpholino) pyrimi...)
Affinity DataIC50: 2.90nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525574((S)-5-(1-(6- (hexahydropyrazino[2,1- c][1,4]oxazin...)
Affinity DataIC50: 3.20nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525560(US11174248, Example 22 | US11174248, Example 23 | ...)
Affinity DataIC50: 3.70nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525553(US11174248, Example 15 | 5-(1-(6-(3- (hydroxymethy...)
Affinity DataIC50: 3.80nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525564(5-(1-(6-(3-methoxy-3- methylazetidin-1- yl)pyrimid...)
Affinity DataIC50: 4.30nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525560(US11174248, Example 22 | US11174248, Example 23 | ...)
Affinity DataIC50: 4.60nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525571(5-(1-(6-(4-(oxetan-3- yl)piperidin-1-yl)pyrimidin-...)
Affinity DataIC50: 5nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525569((S)-5-(1-(6-(2-methyl- morpholino)pyrimidin- 4-yl)...)
Affinity DataIC50: 5.60nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525548(5-(1-(6-((3S,4S)-3-fluoro- 4-hydroxypiperidin-1- y...)
Affinity DataIC50: 6.20nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525573((R)-5-(1-(6- (hexahydropyrazino[2,1- c][1,4]oxazin...)
Affinity DataIC50: 7nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525434(5-(1-(6-((3S,4R)-3- fluoro-4- hydroxypiperidin-1-y...)
Affinity DataIC50: 7.40nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525565(5-(1-(6-(3-cyclopropyl-3- hydroxyazetidin-1- yl)py...)
Affinity DataIC50: 7.40nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525576((S)-5-(1-(6- (hexahydropyrazino[2,1- c][1,4]oxazin...)
Affinity DataIC50: 8.80nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525555(5-(1-(6-((3S,4s,5R and 3R,4s,5S)-4-hydroxy- 3,4,5-...)
Affinity DataIC50: 8.90nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525551(5-(1-(6-(4- (methoxymethyl)-2- azabicyclo[2.1.1]he...)
Affinity DataIC50: 9.30nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525557((R)-5-(1-(6-(3-(2- hydroxypropan-2- yl)pyrrolidin-...)
Affinity DataIC50: 10.7nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525559((S)-5-(1-(2- (methoxymethyl)-6-(3- methyl-4-(oxeta...)
Affinity DataIC50: 10.9nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525463(5-(1-(6-(4-(2- hydroxypropan-2-yl)-2- azabicyclo[2...)
Affinity DataIC50: 12.3nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525558(5-(1-(6-(4-(2- hydroxypropan-2-yl)-2- azabicyclo[2...)
Affinity DataIC50: 16.2nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525419(5-(1-(6-((3R,4S)-3- fluoro-4- hydroxypiperidin-1-y...)
Affinity DataIC50: 18nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM525556(5-(1-(6-(4-(2- hydroxypropan-2-yl)-2- azabicyclo[2...)
Affinity DataIC50: 19.2nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50535647(CHEMBL4442821 | US11174248, Example 48)
Affinity DataIC50: 20.2nMAssay Description: Assays were performed in the presence of 134 μM ATP (Km ATP). Upon completion, the assay was stopped and phosphorylated substrate detected with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent